The first 60 days: Bladder & urothelial cancer
Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval. Below, week by week, is what OnCo's record of Bladder & urothelial cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
- Diagnosis and surveillanceNCCN category Bladder cancer guideline, NCCN Bladder v3.2026
Cystoscopy (white or blue light) and TURBT with muscle in the specimen; re-resection for T1; CT urography; urine cytology; surveillance cystoscopy every 3-12 months by risk.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: MIBC, Diagnosis and surveillance, Low / intermediate-risk NMIBC, High-risk NMIBC, BCG-naive and 1 more.
- RadiologistNamed in the standard of care for: Diagnosis and surveillance.
- SurgeonNamed in the standard of care for: MIBC, Diagnosis and surveillance, Low / intermediate-risk NMIBC, High-risk NMIBC, BCG-naive and 3 more.
- Medical oncologistNamed in the standard of care for: NMIBC, MIBC, Metastatic, Low / intermediate-risk NMIBC and 7 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Muscle-invasive, cisplatin-eligible, Muscle-invasive, cisplatin-ineligible.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
TURBT with single immediate intravesical chemotherapy instillation; intermediate risk adds 1 year of intravesical chemotherapy (gemcitabine/mitomycin) or BCG.
- 2.Muscle-invasive, cisplatin-eligibleNCCN category 1 (NIAGARA regimen); EV+pembro pending label, ESMO-MCBS A (NIAGARA)
Perioperative EV + pembrolizumab (EV-304, positive 2025; filing) or neoadjuvant durvalumab + gemcitabine-cisplatin with adjuvant durvalumab (NIAGARA, approved 2025), then radical cystectomy with lymph node dissection; trimodality bladder preservation (TURBT + chemoradiation) for selected patients.
Perioperative EV + pembrolizumab with cystectomy (EV-303, approved Nov 2025); or cystectomy alone / chemoradiation.
TURBT then BCG induction and 1-3 years maintenance; durvalumab + BCG approved May 2026 (POTOMAC); radical cystectomy for very high-risk (T1 + CIS, variant histology).
TURBT + intravesical BCG; novel intravesical agents for BCG-unresponsive; durvalumab + BCG for high-risk (2026).
Neoadjuvant chemo ± durvalumab → cystectomy → ctDNA-guided atezolizumab or nivolumab.
- 7.MetastaticESMO-MCBS 4 (EV-301 enfortumab vedotin); 3 (TROPHY-U-01), NCCN Guidelines: Bladder Cancer
Enfortumab vedotin + pembrolizumab; erdafitinib (FGFR3); platinum + nivolumab.
- 8.BCG-unresponsive NMIBC (CIS ± papillary)NCCN category 2A (intravesical options); cystectomy preferred, NCCN Bladder v3.2026
Radical cystectomy remains the oncologic gold standard; bladder-sparing options: TAR-200 (Inlexzo, 2025), N-803 + BCG (Anktiva, 2024), nadofaragene firadenovec (2022), pembrolizumab (2020); cretostimogene in registration.
Adjuvant nivolumab for high-risk pathology (CheckMate 274); or ctDNA-guided adjuvant atezolizumab (IMvigor011, approved 2026).
Enfortumab vedotin + pembrolizumab (EV-302); if contraindicated, platinum-gemcitabine followed by avelumab maintenance (JAVELIN Bladder 100) or nivolumab + gemcitabine-cisplatin (CheckMate 901).
Erdafitinib if FGFR3-altered (THOR); platinum chemotherapy if not yet given; disitamab vedotin ± toripalimab (HER2, China); sacituzumab govitecan (US indication withdrawn 2024); trials of TROP2/HER2/bispecific ADCs and sac-TMT.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example FGFR3, PD-L1, HER2, Nectin-4, ctDNA), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Non-muscle-invasive, Muscle-invasive, Upper-tract urothelial carcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
NMIBC
- For my situation (nmibc), which of the standard options do you recommend and why?Guideline options include: TURBT + intravesical BCG; novel intravesical agents for BCG-unresponsive; durvalumab + BCG for high-risk (2026).
- Am I a candidate for Durvalumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
MIBC
- For my situation (mibc), which of the standard options do you recommend and why?Guideline options include: Neoadjuvant chemo ± durvalumab → cystectomy → ctDNA-guided atezolizumab or nivolumab.
- Am I a candidate for Atezolizumab, Signatera, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of IMvigor011 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Metastatic
- For my situation (metastatic), which of the standard options do you recommend and why?Guideline options include: Enfortumab vedotin + pembrolizumab; erdafitinib (FGFR3); platinum + nivolumab.
- Am I a candidate for Enfortumab vedotin, Pembrolizumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EV-302 / KEYNOTE-A39 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Diagnosis and surveillance
- For my situation (diagnosis and surveillance), which of the standard options do you recommend and why?Guideline options include: Cystoscopy (white or blue light) and TURBT with muscle in the specimen; re-resection for T1; CT urography; urine cytology; surveillance cystoscopy every 3-12 months by risk.
Low / intermediate-risk NMIBC
- For my situation (low / intermediate-risk nmibc), which of the standard options do you recommend and why?Guideline options include: TURBT with single immediate intravesical chemotherapy instillation; intermediate risk adds 1 year of intravesical chemotherapy (gemcitabine/mitomycin) or BCG.
High-risk NMIBC, BCG-naive
- For my situation (high-risk nmibc, bcg-naive), which of the standard options do you recommend and why?Guideline options include: TURBT then BCG induction and 1-3 years maintenance; durvalumab + BCG approved May 2026 (POTOMAC); radical cystectomy for very high-risk (T1 + CIS, variant histology).
- Am I a candidate for Intravesical BCG, Durvalumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of POTOMAC apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
BCG-unresponsive NMIBC (CIS ± papillary)
- For my situation (bcg-unresponsive nmibc (cis ± papillary)), which of the standard options do you recommend and why?Guideline options include: Radical cystectomy remains the oncologic gold standard; bladder-sparing options: TAR-200 (Inlexzo, 2025), N-803 + BCG (Anktiva, 2024), nadofaragene firadenovec (2022), pembrolizumab (2020); cretostimogene in registration.
- Am I a candidate for Gemcitabine intravesical system (TAR-200), Nogapendekin alfa inbakicept, Nadofaragene firadenovec or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of SunRISe-1 and BOND-003 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Muscle-invasive, cisplatin-eligible
- For my situation (muscle-invasive, cisplatin-eligible), which of the standard options do you recommend and why?Guideline options include: Perioperative EV + pembrolizumab (EV-304, positive 2025; filing) or neoadjuvant durvalumab + gemcitabine-cisplatin with adjuvant durvalumab (NIAGARA, approved 2025), then radical cystectomy with lymph node dissection; trimodality bladder preservation (TURBT + chemoradiation) for selected patients.
- Am I a candidate for Enfortumab vedotin, Pembrolizumab, Durvalumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EV-304 / KEYNOTE-B15 and NIAGARA apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Muscle-invasive, cisplatin-ineligible
- For my situation (muscle-invasive, cisplatin-ineligible), which of the standard options do you recommend and why?Guideline options include: Perioperative EV + pembrolizumab with cystectomy (EV-303, approved Nov 2025); or cystectomy alone / chemoradiation.
- Am I a candidate for Enfortumab vedotin, Pembrolizumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EV-303 / KEYNOTE-905 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
After cystectomy (no perioperative IO)
- For my situation (after cystectomy (no perioperative io)), which of the standard options do you recommend and why?Guideline options include: Adjuvant nivolumab for high-risk pathology (CheckMate 274); or ctDNA-guided adjuvant atezolizumab (IMvigor011, approved 2026).
- Am I a candidate for Nivolumab, Atezolizumab, Signatera, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CheckMate 274 and IMvigor011 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Metastatic, first line
- For my situation (metastatic, first line), which of the standard options do you recommend and why?Guideline options include: Enfortumab vedotin + pembrolizumab (EV-302); if contraindicated, platinum-gemcitabine followed by avelumab maintenance (JAVELIN Bladder 100) or nivolumab + gemcitabine-cisplatin (CheckMate 901).
- Am I a candidate for Enfortumab vedotin, Pembrolizumab, Avelumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EV-302 / KEYNOTE-A39 and JAVELIN Bladder 100 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Metastatic, later lines
- For my situation (metastatic, later lines), which of the standard options do you recommend and why?Guideline options include: Erdafitinib if FGFR3-altered (THOR); platinum chemotherapy if not yet given; disitamab vedotin ± toripalimab (HER2, China); sacituzumab govitecan (US indication withdrawn 2024); trials of TROP2/HER2/bispecific ADCs and sac-TMT.
- Am I a candidate for Erdafitinib, Disitamab vedotin, Sacituzumab tirumotecan or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of THOR apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Any stage
- Are there clinical trials I could join, for example of Izalontamab brengitecan, AK146D1, Disitamab vedotin, Intismeran autogene?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “BCG supply”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Bladder preservation strategies”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerPhase 3 · recruiting · NCT06592326A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Phase 3 · recruiting · NCT07419295A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerPhase 3 · active · NCT05243550A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
- A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerPhase 3 · recruiting · NCT06774131A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerPhase 3 · active · NCT06331299A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate-risk (IR) of Recurrence
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Bladder & urothelial cancer: the full pageBladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Guidelines comparedNCCN, ESMO and NICE side by side for this cancer.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC): Bladder cancer is divided by whether it has grown into the bladder's muscle wall.
- BCG-unresponsive: The FDA's definition of early bladder cancer that has failed adequate BCG treatment, the population in which most new bladder drugs are first approved.
- Intravesical therapy (BCG and bladder instillations): Putting a drug directly into the bladder through a catheter and leaving it for an hour or two, so it treats the lining without going round the body.
- Transurethral resection of bladder tumour (TURBT): Shaving a bladder tumour away from the inside using a scope passed up the urethra.
- Stoma (colostomy, ileostomy, urostomy): An opening made in the abdominal wall so bowel or urine empties into a bag; may be temporary while a join heals, or permanent when the rectum, anus or bladder has been removed.
- FGFR3 alterations (bladder cancer): FGFR3 is a growth-receptor gene mutated or fused in about a fifth of advanced bladder cancers and most low-grade early ones.
- Organ preservation (watch-and-wait, bladder-sparing, larynx preservation): Curing a cancer with drugs and radiotherapy so that the organ (rectum, bladder, larynx, limb) does not have to be removed, keeping surgery in reserve for the minority whose cancer regrows.
- Platinum-sensitive / platinum-resistant: Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed).
- Radical cystectomy: Removing the bladder (and nearby organs) for bladder cancer that has grown into the muscle wall; urine is then diverted through a stoma or a new bladder made of bowel.
- Maintenance therapy: Ongoing, gentler treatment given after the main course has shrunk the cancer, to hold it in check for as long as possible rather than to shrink it further.
Every term links to the glossary.